In partnership with Lyell Immunopharma, the drug methono has developed a secondary T-cell therapy.

Lyell is a cell therapy company dedicated to the research and development of cell therapy technologies that fundamentally cure cancer.
the company has a range of innovative technologies and advances research into T-cell differentiation, functionality and target specificity to develop curable treatments for solid tumors.
these technologies can be used as a platform for a variety of innovative cell therapies, widely used in a variety of cancers.
this partnership will be combined with Lyell's unique anti-T cell failure technology to protect or maintain T-cell function and the ARTEMIS technology platform acquired from Syracuse.
Syracuse was founded in 2017 by Eureka Therapeutics.
's proprietary ARTEMIS platform is designed to design T-cell therapies that attack cancer using the in-house activation and regulation systems of T-cells.
T-cell receptor (TCR) developed by the platform does not directly link the in-cell signaling domain of the TCR receptor to the costulation protein domain, thus potentially preventing side effects such as overactivation of T-cells and the release of cytokines.
this cooperation, Pharmaceuticals and Lyell hope to seek further cooperation opportunities in China in areas such as research, development and commercialization of new products.
founded in 2016, the pharmaceutical company is an innovative biopharmaceutical company focused on the development, transformation and application of cell immunotherapy, which is in the clinical stage.
public information shows that Drug Ming Juno China has established a mature and stable process system and the international leading cGMP production quality management system, and obtained China's first CD19-targeted CAR-T cell therapy products IND clinical approval (four indications, clinical trials 1, 2 stages), but also in China to carry out clinical research under the IND batch of the largest number of patients in the study of products.
recently, there have been a number of significant developments.
June, the company announced the completion of a $100 million round B financing, while the company's target CD19 CAR-T therapeutic product Ricky Lunsai injection (tentative) in China's listing application was also accepted by China's State Drug Administration (NMPA).
July 15th, Pharmaceuticals and Acepodia reached an exclusive priority licensing cooperation agreement, which gives exclusive priority to the clinical and commercialization of two of its cell immunotherapy candidates in Chinese mainland, Hong Kong and Macau.
July 20, The Drug Ming Juno announced the completion of the acquisition of Syracuse Biopharma (Hong Kong) Co., Ltd., plus code solid tumor T cell immunotherapy research and development.
: s1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .